Biosimilar CT-P43 has matched ustekinumab in the treatment of moderate to severe plaque psoriasis, according to findings reported by AJMC. The result positions CT-P43 as a candidate equivalent to the reference interleukin-12/23 inhibitor in one of dermatology's most established biologic indications.

The equivalence finding arrives at a moment when ustekinumab biosimilars are moving rapidly into the psoriasis market. Ustekinumab, the reference product, has long held a central role in the treatment algorithm for moderate to severe plaque psoriasis, and biosimilar competition is expected to reshape prescribing economics across the indication.

For dermatologists, the claim at the heart of the CT-P43 data is straightforward: comparable performance to the originator biologic in patients with moderate to severe plaque disease. Biosimilar development rests on demonstrating no clinically meaningful differences from the reference product in terms of safety, purity, and potency, and psoriasis has served as a frequent pivotal indication for ustekinumab biosimilars because disease activity can be quantified with validated endpoints.

Clinicians will want to see the specifics that regulators and payers will scrutinize: the responder rates at the primary endpoint, typically measured as PASI improvement at week 12 or later, the study design, and the safety profile across the treatment period. AJMC's report frames the outcome as matching ustekinumab, which is the standard equivalence claim that supports a biosimilar filing in major markets.

The practical stakes for practice economics are considerable. Plaque psoriasis requires long-term biologic therapy, and treatment costs dominate the management equation for moderate to severe disease. A biosimilar that matches the reference product gives payers a lever to push down reimbursement rates, and it gives prescribers a lower-cost option once interchangeability and formulary placement are settled.

The pattern seen with other biosimilar classes in dermatology suggests what comes next. Following approval, uptake typically turns on payer formulary design, rebate structures, and whether pharmacies substitute automatically at the counter. Dermatology practices that track prior authorization requirements and payer preferred-product lists will see CT-P43's commercial relevance decided at the level of coding, substitution policy, and reimbursement rather than in the clinic room.

For patients, equivalence data of this kind carry a different meaning. The clinical question is whether switching from the reference biologic to the biosimilar preserves response, and whether treatment-naïve patients can start on the biosimilar with the same expectations of efficacy. Regulatory frameworks in the United States and Europe have built biosimilar pathways precisely to answer those questions before market entry.

Attention now shifts to the full dataset, the regulatory filings that follow, and the pricing CT-P43's developer sets against the reference product and competing ustekinumab biosimilars already on or nearing the market.